Nasdaq GlobeNewswire

Informa Pharma Intelligence releases Citeline's next generations of Sitetrove, Trialtrove and new API solutions

Del

The industry's most comprehensive clinical trial data and analysis, now delivered to better fit customers' individual needs and workflows

Summary: Informa Pharma Intelligence announces three major releases for its clinical R&D Intelligence suite. The same leading global intelligence trusted by thousands worldwide for over 35 years is now backed by even more powerful, cutting edge technology. These new solutions will allow users to go deeper with clinical trial research than ever before, and will offer new options to help users better integrate Citeline's leading content with their own data.

LONDON, June 19, 2017 (GLOBE NEWSWIRE) -- Informa Pharma Intelligence, the leading provider of drug, device, company, clinical trial, and market intelligence in the competitive pharma and medtech markets announces today the launch of its next generation of Citeline's Sitetrove and Trialtrove solutions, as well as new application programming interfaces (APIs) for Trials and Drugs. The new solutions are designed to deliver unparalleled access to Citeline's robust clinical trial intelligence with greater ease, speed and efficiency than ever before.

"Our next generation of clinical R&D Intelligence solutions are truly market driven," said Linda Blackerby, President of Informa Pharma Intelligence. "We have partnered with hundreds of customers to understand their data needs and workflows, and have developed our new Citeline platform and APIs based directly on their feedback."

The new Trialtrove and Sitetrove provides users with the ability to go even deeper with search criteria to make better and more well-informed critical decisions, gain competitive advantage, save costs on and optimize ROI for their clinical trials. The new APIs will also come with Informa's acclaimed Ask-the-Analyst service, connecting users with therapeutic expert analysts whose average response time to queries is 24 hours or less.

Informa's new Trials and Drugs APIs will enable users to search or stream information directly from Citeline's R&D Intelligence databases into their own systems and embed Informa's quality datasets directly into their own organization's data and workflows, minimizing duplicated effort and time spent acquiring and manipulating data.

"Clinical R&D professionals need to design strategies, develop protocols, plan and execute trials that are on budget and on time," said Nicola Marlin, Vice President of Product. "Our team of scientific analysts live and breathe the data universe to bring our customers a deep understanding of the current clinical trial landscape. The new Citeline platform and API solutions allow users to enjoy the same depth and breadth of specialized, high caliber content, delivered the way they want to better fit their need, internal solutionsand workflows."

"These new releases further reinforce our commitment to our customers to help them gain critical insights into the global clinical trial landscape, realize greater cost-savings and ROI as they develop on their clinical trial programs," stated Michael Hay, Head of Intelligence. "No other intelligence solution comes close."

Attendees at this week's DIA and BIO International conferences will get a sneak preview of these next generation solutions, which will begin launching to customers in July. Additional solutions including the next generation of Citeline's Pharmaprojects and additional APIs for Investigators and Sites are in development for launch later this year.

For more information, visit pharmaintelligence.informa.com.

About Informa Pharma Intelligence
Informa Pharma Intelligence powers a full suite of analysis products - Datamonitor Healthcare, Sitetrove, Trialtrove, Pharmaprojects, Medtrack, Biomedtracker, Scrip, Pink Sheet and In Vivo - to deliver the data needed by the pharmaceutical and biomedical industry to make decisions and create real-world opportunities for growth.

With more than 500 analysts keeping their fingers on the pulse of the industry, no key disease, clinical trial, drug approval or R&D project isn't covered through the breadth and depth of data available to customers. For more information visit pharmaintelligence.informa.com.

About Citeline
Citeline, part of Informa's Pharma Intelligence vertical, is the world's most comprehensive source of real-time R&D intelligence for the pharmaceutical industry, featuring an unmatched intelligence collection and enrichment of global clinical trials, clinical trial investigator profiles and drug development pipelines.

Citeline is the R&D Intelligence arm of Informa's Pharma Intelligence vertical, one of the world's leading providers of drug, device, company, clinical trial and market intelligence in the pharma and medtech markets.  For more information, visit pharmaintelligence.informa.com.

Michael Hay
T: (212) 652-5302
Michael.hay@informa.com




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Informa Business Intelligence via Globenewswire

Om Nasdaq GlobeNewswire

Nasdaq GlobeNewswire
Nasdaq GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

+1 212 401 8700http://www.nasdaqomx.com

NASDAQ (NASDAQ: NDAQ) is a leading provider of trading, exchange technology, information and public company services across six continents.

Følg saker fra Nasdaq GlobeNewswire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Nasdaq GlobeNewswire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Nasdaq GlobeNewswire

Oxford Immunotec to Present at the 29th Annual Piper Jaffray Healthcare Conference21.11.2017 15:15Pressemelding

OXFORD, United Kingdom and MARLBOROUGH, Mass., Nov. 21, 2017 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD), a global, high-growth diagnostics company focused on developing and commercializing proprietary tests for the management of underserved immune-regulated conditions, today announced that Peter Wrighton-Smith, Chief Executive Officer, will present at the 29th Annual Piper Jaffray Healthcare Conference on Tuesday, November 28th, at 12:00 p.m. EST. The conference will be held at the Lotte New York Palace. A live webcast of the presentation will be available online from the investor relations page of the Company's corporate website at www.oxfordimmunotec.com. A webcast replay will be available approximately two hours after the live presentation and will be archived on the website for approximately 90 days. About Oxford Immunotec Oxford Immunotec Global PLC is a global, high-growth diagnostics company focused on developing and comme

CrownBio's Translatable FATZO Model Utilized in Eli Lilly's Preclinical Type 2 Diabetes Research Programs21.11.2017 14:00Pressemelding

SANTA CLARA, Calif., Nov. 21, 2017 (GLOBE NEWSWIRE) -- Crown Bioscience, a wholly-owned subsidiary of Crown Bioscience International (TWSE: ticker 6554) and a global drug discovery and development services company providing translational platforms to advance oncology, inflammation, cardiovascular and metabolic disease research, announces the publication of two new papers. These joint publications illustrate the utility of Crown Bioscience's proprietary FATZO model as a model for obesity and type 2 diabetes in preclinical studies. The research conducted by Crown Bioscience, Eli Lilly and Company and Ball State University was published in two PLOS ONE papers: Peterson et al. Glucose dysregulation and response to common anti-diabetic agents in the FATZO/Pco model PLOS One 2017;12 (6):e0179856, https://doi.org/10.1371/journal.pone.0179856  Droz et al. Correlation of disease severity with body weight and high fat diet in the FATZO/Pco model PLOS One 2017;1

OmniComm Systems Signs Letter of Intent to Acquire Certain Assets of Algorithm and its Subsidiary Algorics21.11.2017 14:00Pressemelding

Acquisition Will Expand OmniComm's Product Line With Data Analytics and Risk-Based Monitoring Solutions FORT LAUDERDALE, Fla., Nov. 21, 2017 (GLOBE NEWSWIRE) -- OmniComm Systems, Inc. (OTCQX:OMCM), a leading global provider of clinical data management technology, and  Algorithm, Inc. and its subsidiaries Algorics Ltd. and Algorithm Informatics Pvt. Ltd. (collectively, "Algorics"), have signed a letter of intent ("LOI"), under which OmniComm will acquire certain assets and assume certain liabilities of Algorics, a provider of clinical analytics solutions and software. By combining forces, the companies expect increased operating efficiency, strengthened traction in the maturing risk-based approach solution area, new marketing opportunities and an expanded portfolio of electronic data capture (EDC) solutions for the global clinical trials industry. The transaction would also provide OmniComm with an office in India, a country of growing importance in t

Port Moresby Stock Exchange (POMSoX) Launches New Nasdaq Trading System21.11.2017 11:31Pressemelding

NEW YORK and PORT MORESBY, Papua New Guinea, Nov. 21, 2017 (GLOBE NEWSWIRE) -- Nasdaq Inc. (NASDAQ:NDAQ) and the Port Moresby Stock Exchange (POMSoX) have announced that POMSoX has gone live with the widely deployed Nasdaq Matching Engine that operates on the Nasdaq Financial Framework platform. The launch of the new trading platform is a result of an upgrade from previous Nasdaq trading technology. The new trading engine will handle the trading of equities in the Papua New Guinea market. POMSoX has been a customer of Nasdaq since 1999.  "The Nasdaq trading platform will allow significant innovation in terms of market design and market offerings," said Johnson Kalo, a POMSoX board member said. "We believe the platform will provide strong support for future growth in the PNG market and provide new business opportunities in areas such as market data distribution." "We are pleased to continue to support POMSoX, a longstanding Nasdaq customer," said Robert Frojd, Regional Man

Euroloan repays EUR 15 million bond and issues three new bonds to fuel growth21.11.2017 10:32Pressemelding

Helsinki, Finland, 2017-11-21 10:32 CET (GLOBE NEWSWIRE) -- Euroloan Group PLC today announced the repayment of a EUR 15 million bond (ISIN code FI4000180351), that had a maturity of 24 months and a coupon of 6%. “We have over ten years of operation built up a level of trust with our investors”, says Tommi Lindfors, Chairman of the Board of Euroloan Group PLC. Euroloan has now issued three new bonds, in total EUR 90 million, to keep up with the rapid growth in its markets.  “Although a minor milestone, this small repayment compared to the new bond issues is a concrete example of how much we have grown over the last few years. We intend to grow a lot more in the future.” “All our markets are growing at an unprecedented pace, and future prospects for further growth are even better. In the pay by invoice and lending business, fast growth means that more funding is required to keep up with demand. This is why we have issued these three new bonds to complement our existing facilit

CloudCraze Joins the Pledge 1% Movement, Makes Commitment to Philanthropic Leadership21.11.2017 08:00Pressemelding

CloudCraze will leverage profit and employee time to improve communities around the world LONDON, Nov. 21, 2017 (GLOBE NEWSWIRE) -- CloudCraze, the enterprise B2B commerce platform built natively on Salesforce, has joined Pledge 1%, a corporate philanthropy movement dedicated to making the community a key stakeholder in every business. Spearheaded by Atlassian, Rally, Salesforce and Tides, Pledge 1% empowers companies to donate 1% of product, 1% of equity, 1% of profit or 1% of employee time to improve communities around the world. CloudCraze is joining an impressive network of entrepreneurs and companies across the globe that have committed to philanthropic efforts through the Pledge 1% movement. By pledging 1% of its profit and employee time, CloudCraze is demonstrating a commitment to philanthropic leadership. "We are incredibly excited that CloudCraze has taken the pledge," said Amy Lesnick, chief executive of Pledge 1%. "CloudCraze can play a pivotal role i

I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.

Besøk vårt presserom